Please login to the form below

Not currently logged in
Email:
Password:

generics

This page shows the latest generics news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Immunotherapy firm Advaxis cuts back, Pfizer wins price gouging appeal

Daily Brief: Immunotherapy firm Advaxis cuts back, Pfizer wins price gouging appeal

The public spending watchdog the National Audit Office has today released its report on the problem of rising generics costs, and the response of the Department of Health (pictured). ... The report found the rising costs was down to hugely increased

Latest news

More from news
Approximately 89 fully matching, plus 1,078 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 6 fully matching, plus 146 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • What does a future-proof rep look like?

    Gone are the days of generic data presentations - these brand value propositions should only form one part of a much richer process.

  • 5 years on from the Brazilian Generics Drugs Act, is there still an opportunity for branded originator drugs?

    The only key difference today between similares and generic drugs, is that similares always have a commercial or brand, while generics are only referred to by the name of the molecule. ... In fact the term “ similares” in Brazil is typically used

  • Indians scalp cowboys in patent war

    The only losers are the generics companies. This is a rare case of indians winning against cowboys, if that is how you view generic manufacturers. ... claims? You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘ BRIC’ markets (Brazil,

  • Antibiotic Resistance: Alarm bells ring louder than ever

    The mature nature of the market means the majority of drugs are cheap-to-produce generics, which would make it difficult for a new drug to be seen as cost effective”. ... Further, the mature nature of the market means the majority of drugs are

More from PMHub
Approximately 0 fully matching, plus 60 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics